-
Curis (CRIS) files for 107.71M share offering by selling stockholders
-
Curis reports Q3 net loss narrows to $7.7M from $10.1M year-over-year
-
Curis (CRIS) Files for 4.62M Share Offering by Selling Stockholders
-
Curis (CRIS) Misses Q2 EPS by 68c
-
Curis reports narrowed Q2 loss, advances emavusertib studies
-
Curis (CRIS) Announces $7M Share and Warrant Offering
-
H.C. Wainwright Assumes Curis (CRIS) at Buy
-
Curis (CRIS) Misses Q1 EPS by 125c
-
Curis (CRIS) PT Lowered to $16 at H.C. Wainwright
-
Curis (CRIS) Provides Q4 Business Update
-
Curis (CRIS) Files for 2.4M Share Offering by Selling Stockholders
-
Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study
-
Curis (CRIS) Misses Q3 EPS by 170c
-
Curis (CRIS) Issues Q3 Business Update
-
Curis (CRIS) PT Lowered to $20 at H.C. Wainwright
-
Curis (CRIS) Prices $12.1M Private Placement at $5.045/unit
-
Laidlaw Reiterates Buy Rating on Curis (CRIS)
-
Jones Trading Reiterates Buy Rating on Curis (CRIS)
-
H.C. Wainwright Reiterates Buy Rating on Curis (CRIS)
-
Curis (CRIS) Misses Q2 EPS by 203c

